• LAST PRICE
    1.8500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.6200/ 4
  • Ask / Lots
    1.8200/ 1
  • Open / Previous Close
    0.0000 / 1.8500
  • Day Range
    ---
  • 52 Week Range
    Low 1.0800
    High 26.4000
  • Volume
    26
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.77
TimeVolumeSONN
09:32 ET3351.78
09:33 ET8671.7257
09:35 ET10001.76
09:55 ET6701.75
10:11 ET3001.75
10:13 ET1001.75
10:22 ET2001.7602
10:33 ET1101.7802
10:40 ET2251.7851
10:44 ET10001.78
10:51 ET3001.785
10:56 ET3001.785
11:05 ET1001.78
11:23 ET1001.77
11:30 ET4921.77
11:32 ET23291.75
11:50 ET6001.75
11:56 ET2001.8
11:57 ET10001.8
12:03 ET3291.71
12:48 ET1001.79
01:00 ET8731.78
01:20 ET8471.78
01:22 ET5001.7799
02:03 ET1001.77
02:07 ET13001.78
02:14 ET13001.78
02:16 ET1001.78
02:23 ET19931.795
02:25 ET1001.7875
02:57 ET2001.79
03:42 ET7741.82
03:44 ET1001.835
03:51 ET2001.83
03:53 ET1001.83
03:55 ET2001.835
03:57 ET1001.85
04:00 ET2171.85
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSONN
Sonnet Biotherapeutics Holdings Inc
5.7M
-0.1x
---
United StatesHOTH
Hoth Therapeutics Inc
5.6M
-0.3x
---
United StatesKPRX
Kiora Pharmaceuticals Inc
5.3M
-0.2x
---
United StatesGTBP
GT Biopharma Inc
5.5M
-0.5x
---
United StatesPCSA
Processa Pharmaceuticals Inc
4.6M
-0.1x
---
United StatesSHPH
Shuttle Pharmaceuticals Holdings Inc
6.3M
-1.0x
---
As of 2024-02-27

Company Information

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Contact Information

Headquarters
100 Overlook Center, Suite 102PRINCETON, NJ, United States 08540
Phone
609-375-2227
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Pankaj Mohan
Chief Financial Officer
John Cross
Chief Scientific Officer
John Cini
Chief Technical Officer
Susan Dexter
Chief Medical Officer
Richard Kenney

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.7M
Revenue (TTM)
$129.2K
Shares Outstanding
3.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.61
EPS
$-12.91
Book Value
$-0.13
P/E Ratio
-0.1x
Price/Sales (TTM)
44.0
Price/Cash Flow (TTM)
---
Operating Margin
-11,192.10%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.